<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01277640</url>
  </required_header>
  <id_info>
    <org_study_id>MTN-012/IPM 010</org_study_id>
    <nct_id>NCT01277640</nct_id>
  </id_info>
  <brief_title>Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures</brief_title>
  <official_title>Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of male genitalia when exposed to&#xD;
      dapivirine gel following seven once daily applications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the genitourinary safety of dapivirine gel (0.05%), the endpoint was the proportion of men subjected to dapivirine gel or placebo gel experiencing specific, protocol-defined safety events during the study (see description).</measure>
    <time_frame>8 days</time_frame>
    <description>Any evidence of Grade 2 or higher male genitourinary adverse event(s) as defined by the DAIDS AE Grading Table Version 1.0, December 2004 (Clarification dated August 2009), Addendum 2 (Male Genital Toxicity Table for Use in Topical Microbicide Studies)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetics in plasma following 7 days of once daily penile application of dapivirine gel (0.05%)</measure>
    <time_frame>8 days</time_frame>
    <description>Dapivirine concentrations in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the systemic safety following 7 days of once daily penile application of dapivirine gel (0.05%)</measure>
    <time_frame>8 days</time_frame>
    <description>Grade 2 and higher clinical and laboratory adverse events as defined by the DAIDS AE Grading Table Version 1.0, December 2004 (Clarification dated August 2009) and the Male Genital Toxicity Table for Use in Topical Microbicide Studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the acceptability following 7 days of once daily penile application of dapivirine gel (0.05%)</measure>
    <time_frame>8 days</time_frame>
    <description>Proportion of participants who at their Final Clinic Visit report via the acceptability questionnaire, that they would be very likely to use the candidate microbicide during sexual intercourse in the future</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Topical Penile Exposures</condition>
  <arm_group>
    <arm_group_label>matched placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>universal placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>dapivirine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapivirine</intervention_name>
    <description>dosage form: gel 0.05%&#xD;
dosage: 2.5g&#xD;
frequency: once daily&#xD;
duration: 7 days</description>
    <arm_group_label>dapivirine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matched placebo</intervention_name>
    <description>dosage form: gel, no api&#xD;
dosage: 2.5g&#xD;
frequency: once daily&#xD;
duration: 7 days</description>
    <arm_group_label>matched placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>universal placebo</intervention_name>
    <description>dosage form: gel, HEC-based&#xD;
dosage: 2.5g&#xD;
frequency: once daily&#xD;
duration: 7 days</description>
    <arm_group_label>universal placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age at Screening, verified per site standard operating procedure&#xD;
             (SOP)&#xD;
&#xD;
          -  Able and willing to provide written informed consent to be screened for and take part&#xD;
             in the study&#xD;
&#xD;
          -  At Screening, able and willing to provide adequate locator information, as defined per&#xD;
             site SOP&#xD;
&#xD;
          -  Able and willing to communicate in written and spoken English&#xD;
&#xD;
          -  HIV-uninfected at Screening per Algorithm in Appendix II&#xD;
&#xD;
          -  In general good health, according to the clinical judgment of the Investigator of&#xD;
             Record (IoR) or designee&#xD;
&#xD;
          -  Willing to abstain from vaginal, oral and anal intercourse (including receptive anal&#xD;
             intercourse), even with a condom; masturbation, and other activities that may cause&#xD;
             irritation or injury to the penis during study participation&#xD;
&#xD;
          -  Willing to abstain from using any genitally-applied preparations (except use of usual&#xD;
             cleansing products for genital hygiene) other than the study product during study&#xD;
             participation&#xD;
&#xD;
          -  Willing to abstain from non-urgent surgical procedures of the penis/GU area for the&#xD;
             duration of study participation (e.g. circumcision)&#xD;
&#xD;
          -  At Screening and Enrollment, agrees not to participate in other research studies&#xD;
             involving drugs, medical devices, or genital products for the duration of study&#xD;
             participation (until all follow-up visits are completed)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant report of any of the following:&#xD;
&#xD;
               -  Known adverse reaction to any of the study products or components of the study&#xD;
                  products (ever)&#xD;
&#xD;
               -  Post-exposure prophylaxis (PEP) for HIV exposure within 6 months prior to&#xD;
                  Enrollment&#xD;
&#xD;
               -  Penile procedures (e.g. biopsy, circumcision) within 42 days or less prior to&#xD;
                  Enrollment&#xD;
&#xD;
               -  Participation in any other research study involving drugs, medical devices, or&#xD;
                  genital products within 30 days or less prior to Enrollment&#xD;
&#xD;
               -  Within the three months prior to Enrollment, history of a non-gonococcal&#xD;
                  urethritis and/or sexually transmitted infection (STI), including outbreak of&#xD;
                  genital herpes or condylomata&#xD;
&#xD;
               -  For uncircumcised men, the treatment of candidal balanoposthitis/ balanitis&#xD;
                  within 30 days prior to Enrollment&#xD;
&#xD;
               -  History of recurrent dermatosis (e.g. eczema)&#xD;
&#xD;
               -  Non-therapeutic injection drug use in the 12 months prior to Screening&#xD;
&#xD;
               -  Currently using an immunosuppressant (with the exception of local nongenital use&#xD;
                  of low potency products e.g. inhaled corticosteroid for asthma)&#xD;
&#xD;
               -  Has any of the following laboratory abnormalities at Screening:&#xD;
&#xD;
                    -  Hemoglobin &lt; 10.0 g/dL&#xD;
&#xD;
                    -  Platelet count &lt; 100,000/mm3&#xD;
&#xD;
                    -  White blood cell count &lt; 2,000 cells/mm3&#xD;
&#xD;
                    -  Alanine transaminase (ALT) and/or aspartate aminotransferase (AST) &gt; 2.5x&#xD;
                       the site laboratory upper limit of normal (ULN)&#xD;
&#xD;
                    -  Serum creatinine &gt; 1.3x the site laboratory ULN&#xD;
&#xD;
                    -  Calculated creatinine clearance less than 80 mL/min by the Cockcroft-Gault&#xD;
                       formula where creatinine clearance in mL/min = (140-age in years) x (weight&#xD;
                       in kg) x 0.85/72 x serum creatinine in mg/dL Note: Otherwise eligible&#xD;
                       participants with any of the above exclusionary laboratory results may be&#xD;
                       re-tested. If a participant is re-tested and a non exclusionary result is&#xD;
                       documented within 30 days of providing informed consent for Screening, the&#xD;
                       participant may be enrolled.&#xD;
&#xD;
          -  At Screening or Enrollment, diagnosed with STI or reproductive tract infection (RTI)&#xD;
             requiring treatment, per current Centers for Disease Control and Prevention (CDC)&#xD;
             guidelines&#xD;
&#xD;
          -  At Screening or Enrollment, has a clinically apparent Grade 1 or higher genital exam&#xD;
             finding (observed by study staff)&#xD;
&#xD;
          -  At Screening or Enrollment, has Grade 1 or higher genital or urinary symptoms&#xD;
&#xD;
          -  At Screening or Enrollment, diagnosed with phimosis or hypospadias&#xD;
&#xD;
          -  At Screening or Enrollment, penile, scrotal piercing or penile tattoos observed during&#xD;
             genital examination&#xD;
&#xD;
          -  Has any other condition that, in the opinion of the IoR/designee, would preclude&#xD;
             informed consent, make study participation unsafe, complicate interpretation of study&#xD;
             outcome data, or otherwise interfere with achieving the study objectives&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ross D. Cranston, MD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Infectious Diseases, University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cranston RD, Hoesley C, Carballo-Diéguez A, Hendrix CW, Husnik M, Levy L, Hall W, Soto-Torres L, Nel AM. A randomized male tolerance study of dapivirine gel following multiple topical penile exposures (MTN 012/IPM 010). AIDS Res Hum Retroviruses. 2014 Feb;30(2):184-9. doi: 10.1089/AID.2013.0170. Epub 2013 Oct 26.</citation>
    <PMID>24070431</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>January 13, 2011</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>male tolerance</keyword>
  <keyword>HIV-1</keyword>
  <keyword>microbicide</keyword>
  <keyword>dapivirine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapivirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

